Patients with dementia and their families may express frustration about the limited number of options for improving cognitive symptoms, but they are not without choices. Here we will review a number of pharmacological treatment options for Alzheimer’s disease (AD) and other major types of dementia.
Prediction of suicidal behavior has long been considered more of an art than a science, although the use of clinical and demographic features can help improve risk assessment. An accurate biological test or “biomarker” for suicidality would be valuable, and a recent study takes us one step closer to that goal.
The FDA has approved vortioxetine (Brintellix) for the treatment of major depressive disorder (MDD). Brintellix is a novel antidepressant thought to work by enhancing serotonergic acitivty as a serotonin (5-HT) reuptake inhibitor and agonist of the 5-HT1A receptor, among other mechanisms.
Scientists have discovered that the brains of mice clean toxins from between cells while they are sleeping. During sleep, the space between brain cells increases by about 60%, allowing the glymphatic system, or the brain’s “plumbing” system, to flush the brain with fluid.
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.